Cystic Fibrosis (CF) Therapeutics Market by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, and CFTR Modulators) and Route of Administration (Oral and Inhaled): Global Opportunity Analysis and Industry Forecast, 2019-2026
The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient’s ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a sweat test and recommend additional testing to confirm the diagnosis.
Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
- By Drug Class
- Pancreatic Enzyme Supplements
- Mucolytic
- Bronchodilators
- CFTR Modulators
- By Route of Administration
- Oral
- Inhaled
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Genentech, Inc.
- Novartis AG
- Gilead Sciences, Inc.
- Vertex Pharmaceuticals Incorporated
- AbbVie Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Allergan plc.
- Pharmaxis Ltd.
- Mylan N.V.
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Cxo Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Porter’S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)
3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis
3.4.2. Restraints
3.4.2.1. Low Awareness In Developing Nations
3.4.3. Opportunity
3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics
CHAPTER 4: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Pancreatic Enzyme Supplements
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Mucolytics
4.3.1. Key Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Bronchodilators
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Cftr Modulators
4.5.1. Key Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country
CHAPTER 5: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Oral
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Inhale
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
CHAPTER 6: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Trends And Opportunities
6.2.2. North America Market Size And Forecast, By Country
6.2.2.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration
6.2.2.3. Canada Market Size And Forecast, By Drug Class
6.2.2.4. Canada Market Size And Forecast, By Route Of Administration
6.2.2.5. Mexico Market Size And Forecast, By Drug Class
6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Route Of Administration
6.3. Europe
6.3.1. Key Trends And Opportunities
6.3.2. Europe Market Size And Forecast, By Country
6.3.2.1. Germany Market Size And Forecast, By Drug Class
6.3.2.2. Germany Market Size And Forecast, By Route Of Administration
6.3.2.3. Uk Market Size And Forecast, By Drug Class
6.3.2.4. Uk Market Size And Forecast, By Route Of Administration
6.3.2.5. France Market Size And Forecast, By Drug Class
6.3.2.6. France Market Size And Forecast, By Route Of Administration
6.3.2.7. Rest Of Europe Market Size And Forecast, By Drug Class
6.3.2.8. Rest Of Europe Market Size And Forecast, By Route Of Administration
6.3.3. Europe Market Size And Forecast, By Drug Class
6.4. Asia-Pacific
6.4.1. Key Trends And Opportunities
6.4.2. Asia-Pacific Market Size And Forecast, By Country
6.4.2.1. Japan Market Size And Forecast, By Drug Class
6.4.2.2. Japan Market Size And Forecast, By Route Of Administration
6.4.2.3. China Market Size And Forecast, By Drug Class
6.4.2.4. China Market Size And Forecast, By Route Of Administration
6.4.2.5. India Market Size And Forecast, By Drug Class
6.4.2.6. India Market Size And Forecast, By Route Of Administration
6.4.2.7. Australia Market Size And Forecast, By Drug Class
6.4.2.8. Australia Market Size And Forecast, By Route Of Administration
6.4.2.9. Rest Of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.10. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Route Of Administration
6.5. Lamea
6.5.1. Key Market Trends And Opportunities
6.5.2. Lamea Market Size And Forecast, By Country
6.5.2.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.2. Brazil Market Size And Forecast, By Route Of Administration
6.5.2.3. South Africa Market Size And Forecast, By Drug Class
6.5.2.4. South Africa Market Size And Forecast, By Route Of Administration
6.5.2.5. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.6. Saudi Arabia Market Size And Forecast, By Route Of Administration
6.5.2.7. Rest Of Lamea Market Size And Forecast, By Drug Class
6.5.2.8. Rest Of Lamea Market Size And Forecast, By Route Of Administration
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Route Of Administration
CHAPTER 7: COMPANY PROFILES
7.1. F. Hoffmann-La Roche Ag
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Novartis Ag
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Gilead Sciences, Inc.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Vertex Pharmaceuticals Incorporated
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments
7.5. Abbvie Inc.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves And Developments
7.6. Glaxosmithkline Plc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Teva Pharmaceutical Industries Ltd.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Allergan Plc
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Pharmaxis Ltd
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.10. Mylan N.V
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Cxo Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Porter’S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)
3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis
3.4.2. Restraints
3.4.2.1. Low Awareness In Developing Nations
3.4.3. Opportunity
3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics
CHAPTER 4: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Pancreatic Enzyme Supplements
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Mucolytics
4.3.1. Key Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Bronchodilators
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Cftr Modulators
4.5.1. Key Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country
CHAPTER 5: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Oral
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Inhale
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
CHAPTER 6: CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Trends And Opportunities
6.2.2. North America Market Size And Forecast, By Country
6.2.2.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration
6.2.2.3. Canada Market Size And Forecast, By Drug Class
6.2.2.4. Canada Market Size And Forecast, By Route Of Administration
6.2.2.5. Mexico Market Size And Forecast, By Drug Class
6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Route Of Administration
6.3. Europe
6.3.1. Key Trends And Opportunities
6.3.2. Europe Market Size And Forecast, By Country
6.3.2.1. Germany Market Size And Forecast, By Drug Class
6.3.2.2. Germany Market Size And Forecast, By Route Of Administration
6.3.2.3. Uk Market Size And Forecast, By Drug Class
6.3.2.4. Uk Market Size And Forecast, By Route Of Administration
6.3.2.5. France Market Size And Forecast, By Drug Class
6.3.2.6. France Market Size And Forecast, By Route Of Administration
6.3.2.7. Rest Of Europe Market Size And Forecast, By Drug Class
6.3.2.8. Rest Of Europe Market Size And Forecast, By Route Of Administration
6.3.3. Europe Market Size And Forecast, By Drug Class
6.4. Asia-Pacific
6.4.1. Key Trends And Opportunities
6.4.2. Asia-Pacific Market Size And Forecast, By Country
6.4.2.1. Japan Market Size And Forecast, By Drug Class
6.4.2.2. Japan Market Size And Forecast, By Route Of Administration
6.4.2.3. China Market Size And Forecast, By Drug Class
6.4.2.4. China Market Size And Forecast, By Route Of Administration
6.4.2.5. India Market Size And Forecast, By Drug Class
6.4.2.6. India Market Size And Forecast, By Route Of Administration
6.4.2.7. Australia Market Size And Forecast, By Drug Class
6.4.2.8. Australia Market Size And Forecast, By Route Of Administration
6.4.2.9. Rest Of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.10. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Route Of Administration
6.5. Lamea
6.5.1. Key Market Trends And Opportunities
6.5.2. Lamea Market Size And Forecast, By Country
6.5.2.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.2. Brazil Market Size And Forecast, By Route Of Administration
6.5.2.3. South Africa Market Size And Forecast, By Drug Class
6.5.2.4. South Africa Market Size And Forecast, By Route Of Administration
6.5.2.5. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.6. Saudi Arabia Market Size And Forecast, By Route Of Administration
6.5.2.7. Rest Of Lamea Market Size And Forecast, By Drug Class
6.5.2.8. Rest Of Lamea Market Size And Forecast, By Route Of Administration
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Route Of Administration
CHAPTER 7: COMPANY PROFILES
7.1. F. Hoffmann-La Roche Ag
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Novartis Ag
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Gilead Sciences, Inc.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Vertex Pharmaceuticals Incorporated
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments
7.5. Abbvie Inc.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves And Developments
7.6. Glaxosmithkline Plc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Teva Pharmaceutical Industries Ltd.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Allergan Plc
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Pharmaxis Ltd
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.10. Mylan N.V
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
LIST OF TABLES
Table 01. Global Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 02. Global Pancreatic Enzyme Supplements, By Region, 2018–2026 ($Million)
Table 03. @List of Mucolytics Used To Treat Cystic Fibrosis
Table 04. Global Mucolytics Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 05. @List of Bronchodilators Used To Treat Cystic Fibrosis
Table 06. Global Bronchodilators Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 07. @List of Cftrs Used To Treat Cystic Fibrosis
Table 08. Global Cftr Modulator Market, By Region, 2018–2026 ($Million)
Table 09. Global Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 10. Global Cystic Fibrosis Therapeutics Market For Oral Route of Administration, By Region, 2018–2026 ($Million)
Table 11. Global Cystic Fibrosis Therapeutics Market For Inhale Route of Administration, By Region, 2018–2026 ($Million)
Table 12. Global Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 13. North America Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 14. U.S. Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 15. U.S. Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 16. Canada Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 17. Canada Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 18. Mexico Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 19. Mexico Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 20. North America Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 21. North America Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 22. Europe Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 23. Germany Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 24. Germany Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 25. Uk Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 26. Uk Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 27. France Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 28. France Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 29. Rest of Europe Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 30. Rest of Europe Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 31. Europe Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 32. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 33. Japan Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 34. Japan Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 35. China Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 36. China Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 37. India Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 38. India Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 39. Australia Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 40. Australia Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 41. Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 42. Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 43. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 44. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 45. Lamea Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 46. Brazil Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 47. Brazil Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 48. South Africa Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 49. South Africa Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 50. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 51. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 52. Rest of Lamea Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 53. Rest of Lamea Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 54. Lamea Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 55. Lamea Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 56. Roche: Company Snapshot
Table 57. Roche: Operating Segments
Table 58. Roche Plc: Product Portfolio
Table 59. Novartis Ag Inc.: Company Snapshot
Table 60. Novartis Ag Inc.: Operating Segments
Table 61. Novartis Ag Inc.: Product Portfolio
Table 62. Gilead Sciences, Inc.: Company Snapshot
Table 63. Gilead Sciences, Inc.: Operating Segments
Table 64. Gilead Sciences, Inc.: Product Portfolio:
Table 65. Vertex Pharmaceuticals Incorporated: Company Snapshot
Table 66. Vertex Pharmaceuticals Incorporated: Operating Segments
Table 67. Vertex Pharmaceuticals Incorporated: Product Portfolio
Table 68. Abbvie Inc.: Company Snapshot
Table 69. Abbvie Inc.: Operating Segments
Table 70. Abbvie Inc.: Product Portfolio
Table 71. Glaxosmithkline Plc.: Company Snapshot
Table 72. Glaxosmithkline Plc.: Operating Segments
Table 73. Glaxosmithkline Plc.: Product Portfolio
Table 74. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 75. Teva Pharmaceutical Industries Pharmaceutical Industries Ltd.: Operating Segments
Table 76. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 77. Allergan Plc: Company Snapshot
Table 78. Allergan Plc: Operating Segments
Table 79. Allergan Plc: Product Portfolio
Table 80. Pharmaxis Ltd: Company Snapshot
Table 81. Pharmaxis Ltd: Product Segments
Table 82. Pharmaxis Ltd: Product Portfolio
Table 83. Mylan N.V.: Company Snapshot
Table 84. Mylan N.V.: Operating Segments
Table 85. Mylan N.V: Product Portfolio
Table 01. Global Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 02. Global Pancreatic Enzyme Supplements, By Region, 2018–2026 ($Million)
Table 03. @List of Mucolytics Used To Treat Cystic Fibrosis
Table 04. Global Mucolytics Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 05. @List of Bronchodilators Used To Treat Cystic Fibrosis
Table 06. Global Bronchodilators Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 07. @List of Cftrs Used To Treat Cystic Fibrosis
Table 08. Global Cftr Modulator Market, By Region, 2018–2026 ($Million)
Table 09. Global Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 10. Global Cystic Fibrosis Therapeutics Market For Oral Route of Administration, By Region, 2018–2026 ($Million)
Table 11. Global Cystic Fibrosis Therapeutics Market For Inhale Route of Administration, By Region, 2018–2026 ($Million)
Table 12. Global Cystic Fibrosis Therapeutics Market, By Region, 2018–2026 ($Million)
Table 13. North America Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 14. U.S. Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 15. U.S. Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 16. Canada Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 17. Canada Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 18. Mexico Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 19. Mexico Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 20. North America Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 21. North America Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 22. Europe Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 23. Germany Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 24. Germany Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 25. Uk Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 26. Uk Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 27. France Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 28. France Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 29. Rest of Europe Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 30. Rest of Europe Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 31. Europe Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 32. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 33. Japan Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 34. Japan Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 35. China Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 36. China Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 37. India Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 38. India Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 39. Australia Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 40. Australia Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 41. Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 42. Rest of Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 43. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 44. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 45. Lamea Cystic Fibrosis Therapeutics Market, By Country, 2018–2026 ($Million)
Table 46. Brazil Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 47. Brazil Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 48. South Africa Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 49. South Africa Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 50. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 51. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 52. Rest of Lamea Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 53. Rest of Lamea Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 54. Lamea Cystic Fibrosis Therapeutics Market, By Drug Class, 2018–2026 ($Million)
Table 55. Lamea Cystic Fibrosis Therapeutics Market, By Route of Administration, 2018–2026 ($Million)
Table 56. Roche: Company Snapshot
Table 57. Roche: Operating Segments
Table 58. Roche Plc: Product Portfolio
Table 59. Novartis Ag Inc.: Company Snapshot
Table 60. Novartis Ag Inc.: Operating Segments
Table 61. Novartis Ag Inc.: Product Portfolio
Table 62. Gilead Sciences, Inc.: Company Snapshot
Table 63. Gilead Sciences, Inc.: Operating Segments
Table 64. Gilead Sciences, Inc.: Product Portfolio:
Table 65. Vertex Pharmaceuticals Incorporated: Company Snapshot
Table 66. Vertex Pharmaceuticals Incorporated: Operating Segments
Table 67. Vertex Pharmaceuticals Incorporated: Product Portfolio
Table 68. Abbvie Inc.: Company Snapshot
Table 69. Abbvie Inc.: Operating Segments
Table 70. Abbvie Inc.: Product Portfolio
Table 71. Glaxosmithkline Plc.: Company Snapshot
Table 72. Glaxosmithkline Plc.: Operating Segments
Table 73. Glaxosmithkline Plc.: Product Portfolio
Table 74. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 75. Teva Pharmaceutical Industries Pharmaceutical Industries Ltd.: Operating Segments
Table 76. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 77. Allergan Plc: Company Snapshot
Table 78. Allergan Plc: Operating Segments
Table 79. Allergan Plc: Product Portfolio
Table 80. Pharmaxis Ltd: Company Snapshot
Table 81. Pharmaxis Ltd: Product Segments
Table 82. Pharmaxis Ltd: Product Portfolio
Table 83. Mylan N.V.: Company Snapshot
Table 84. Mylan N.V.: Operating Segments
Table 85. Mylan N.V: Product Portfolio
LIST OF FIGURES
Figure 01. Cystic Fibrosis Therapeutics Market Segmentation
Figure 02. Low Bargaining Power of Suppliers
Figure 03. High Bargaining Power of Buyers
Figure 04. High Threat of Substitution
Figure 05. High Threat of New Entrants
Figure 06. High Competitive Rivalry
Figure 07. Top Player Positioning
Figure 08. Global Cystic Fibrosis Therapeutics Market: Drivers, Restraints, And Opportunities
Figure 09. Comparative Share Analysis of Pancreatic Enzyme Supplements Market, By Country, 2018 & 2026 (%)
Figure 10. Comparative Share Analysis of Mucolytics Cystic Fibrosis Therapeutics Market, By Country, 2018 & 2026 (%)
Figure 11. Comparative Share Analysis of Bronchodilators Cystic Fibrosis Therapeutics Market, By Country, 2018 & 2026 (%)
Figure 12. Comparative Share Analysis of Cftr Modulator Market, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Cystic Fibrosis Therapeutics Market For Oral Route of Administration By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Cystic Fibrosis Therapeutics Market For Inhale Route of Administration By Country, 2018 & 2026 (%)
Figure 15. Roche: Revenue Share By Geography, 2018 (%)
Figure 16. Roche: Revenue Share By Segment, 2018 (%)
Figure 17. Roche: Revenue Share By Geography, 2018 (%)
Figure 18. Novartis Ag Inc: Net Sales, 2016–2018 ($Million)
Figure 19. Novartis Ag Inc: Revenue Share By Segment, 2018 (%)
Figure 20. Novartis Ag Inc..: Revenue Share By Region, 2018(%)
Figure 21. Gilead Sciences Inc.: Net Sales, 2016–2018 ($Million)
Figure 22. Gilead Sciences Inc..: Revenue Share By Region, 2018(%)
Figure 23. Gilead Sciences Inc.: Revenue Share By Segment, 2018 (%)
Figure 24. Vertex Pharmaceutical Inc..: Net Sales, 2016–2018 ($Million)
Figure 25. Vertex Pharmaceutical Inc.: Revenue Share By Segment, 2018 (%)
Figure 26. Abbvie Inc..: Net Sales, 2016–2018 ($Million)
Figure 27. Abbvie Inc..: Revenue Share By Regions, 2018 (%)
Figure 28. Abbvie Inc..: Revenue Share By Segment, 2018 (%)
Figure 29. Glaxosmithkline Plc.: Net Sales, 2016–2018 ($Million)
Figure 30. Glaxosmithkline Plc.: Revenue Share By Region, 2018(%)
Figure 31. Glaxosmithkline Plc.: Revenue Share By Segment, 2018 (%)
Figure 32. Teva Pharmaceutical Industries: Net Sales, 2016–2018 ($Million)
Figure 33. Teva Pharmaceutical Industries: Revenue Share By Segments 2018 ($Million)
Figure 34. Allergan Plc: Net Sales, 2016–2018 ($Million)
Figure 35. Allergan Plc: Revenue Share By Segment, 2018 (%)
Figure 36. Mylan N.V.: Net Sales, 2016–2018 ($Million)
Figure 37. Mylan N.V.: Revenue Share By Region, 2018(%)
Figure 01. Cystic Fibrosis Therapeutics Market Segmentation
Figure 02. Low Bargaining Power of Suppliers
Figure 03. High Bargaining Power of Buyers
Figure 04. High Threat of Substitution
Figure 05. High Threat of New Entrants
Figure 06. High Competitive Rivalry
Figure 07. Top Player Positioning
Figure 08. Global Cystic Fibrosis Therapeutics Market: Drivers, Restraints, And Opportunities
Figure 09. Comparative Share Analysis of Pancreatic Enzyme Supplements Market, By Country, 2018 & 2026 (%)
Figure 10. Comparative Share Analysis of Mucolytics Cystic Fibrosis Therapeutics Market, By Country, 2018 & 2026 (%)
Figure 11. Comparative Share Analysis of Bronchodilators Cystic Fibrosis Therapeutics Market, By Country, 2018 & 2026 (%)
Figure 12. Comparative Share Analysis of Cftr Modulator Market, By Country, 2018 & 2026 (%)
Figure 13. Comparative Share Analysis of Cystic Fibrosis Therapeutics Market For Oral Route of Administration By Country, 2018 & 2026 (%)
Figure 14. Comparative Share Analysis of Cystic Fibrosis Therapeutics Market For Inhale Route of Administration By Country, 2018 & 2026 (%)
Figure 15. Roche: Revenue Share By Geography, 2018 (%)
Figure 16. Roche: Revenue Share By Segment, 2018 (%)
Figure 17. Roche: Revenue Share By Geography, 2018 (%)
Figure 18. Novartis Ag Inc: Net Sales, 2016–2018 ($Million)
Figure 19. Novartis Ag Inc: Revenue Share By Segment, 2018 (%)
Figure 20. Novartis Ag Inc..: Revenue Share By Region, 2018(%)
Figure 21. Gilead Sciences Inc.: Net Sales, 2016–2018 ($Million)
Figure 22. Gilead Sciences Inc..: Revenue Share By Region, 2018(%)
Figure 23. Gilead Sciences Inc.: Revenue Share By Segment, 2018 (%)
Figure 24. Vertex Pharmaceutical Inc..: Net Sales, 2016–2018 ($Million)
Figure 25. Vertex Pharmaceutical Inc.: Revenue Share By Segment, 2018 (%)
Figure 26. Abbvie Inc..: Net Sales, 2016–2018 ($Million)
Figure 27. Abbvie Inc..: Revenue Share By Regions, 2018 (%)
Figure 28. Abbvie Inc..: Revenue Share By Segment, 2018 (%)
Figure 29. Glaxosmithkline Plc.: Net Sales, 2016–2018 ($Million)
Figure 30. Glaxosmithkline Plc.: Revenue Share By Region, 2018(%)
Figure 31. Glaxosmithkline Plc.: Revenue Share By Segment, 2018 (%)
Figure 32. Teva Pharmaceutical Industries: Net Sales, 2016–2018 ($Million)
Figure 33. Teva Pharmaceutical Industries: Revenue Share By Segments 2018 ($Million)
Figure 34. Allergan Plc: Net Sales, 2016–2018 ($Million)
Figure 35. Allergan Plc: Revenue Share By Segment, 2018 (%)
Figure 36. Mylan N.V.: Net Sales, 2016–2018 ($Million)
Figure 37. Mylan N.V.: Revenue Share By Region, 2018(%)
